title: Androgen receptor splice variant 7 (AR-V7) and drug efficacy in castration-resistant prostate cancer: Biomarker for treatment selection exclusion or inclusion?
abstract: Currently there are no molecular biomarkers used to help guide treatment selection for those patients with castration-resistant prostate cancer. A recent study published in JAMA Oncology (Antonarakis et al.) presents evidence supporting the potential use of androgen receptor splice variant 7 as a biomarker for optimal treatment selection in this population.
authors.affiliation: a Molecular Pharmacology Section, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health , Bethesda , Maryland , USA.
authors.forename: Crystal R
authors.initials: CR
authors.lastname: Leibrand
authors.affiliation: a Molecular Pharmacology Section, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health , Bethesda , Maryland , USA.
authors.forename: Douglas K
authors.initials: DK
authors.lastname: Price
authors.affiliation: a Molecular Pharmacology Section, Genitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health , Bethesda , Maryland , USA.
authors.forename: William D
authors.initials: WD
authors.lastname: Figg
mesh_terms: D015415:Biomarkers; D006801:Humans; D008297:Male; D064129:Prostatic Neoplasms, Castration-Resistant / Q000188:drug therapy*; D020033:Protein Isoforms / Q000235:genetics*; D011944:Receptors, Androgen / Q000235:genetics*
chemical_list: C410798:AR protein, human; D015415:Biomarkers; D020033:Protein Isoforms; D011944:Receptors, Androgen
keywords: Androgen receptor; prostate cancer; splice variants